LONDON, March 14, 2017
/PRNewswire/ -- Smith & Nephew (NYSE: SNN; LSE: SN), the
global medical technology business, today announces the upcoming
full market release of its NAVIO hand-held robotics-assisted total
knee arthroplasty (TKA) system. Smith & Nephew will be hosting
live hands-on demonstrations for surgeons at the 2017 Annual
American Academy of Orthopaedic Surgeons meeting in San Diego, CA, March
15-17 (booth # 5133).
The NAVIO Surgical System total knee application is expected to
enter full market release in the second quarter of 2017, 510(k)
pending, with Smith & Nephew's JOURNEY II, LEGION and GENESIS
II Total Knee Systems.
The NAVIO robotic-assisted total knee application is designed to
deliver consistent and accurate results through the utilization of
a surgeon controlled robotics-assisted hand piece, coupled with
NAVIO specific cut guides. This unique combination yields an
intuitive and efficient workflow for the entire surgical team.
In addition, the versatile NAVIO planning software enables
precise implant alignment and ligament balance, without the need
for a pre-operative CT scan. Eliminating the dependency on
pre-operative imaging allows the surgeon to seamlessly plan for
either a unicompartmental or total knee procedure at the time of
surgery.
"I have experience with several robotic systems and my
experience with the NAVIO Surgical System has been phenomenal. Both
NAVIO UKA and TKA
applications allow me freedom as a surgeon, unlike other
robotic options, because it is imageless. I can easily plan
and correct for significant deformities and retained hardware with
confidence. I love the direct interface with the system itself,
putting me back in control.
Additionally, the cost of the system including the capital
investment, lack of advanced imaging and its portability make it
affordable for both hospitals and ASCs" says Jimmy Chow, M.D, Director of Orthopaedics:
Hip & Joint, Phoenix St. Luke's Medical Center.
About Smith & Nephew
Smith & Nephew is a global medical technology business
dedicated to helping healthcare professionals improve people's
lives. With leadership positions in Orthopaedic Reconstruction,
Advanced Wound Management, Sports Medicine and Trauma &
Extremities, Smith & Nephew has around 15,000 employees and a
presence in more than 100 countries. Annual sales in 2016 were more
than $4.6 billion. Smith & Nephew
is a member of the FTSE100 (LSE:SN, NYSE:SNN).
For more information about Smith & Nephew, please visit our
website www.smith-nephew.com, follow @SmithNephewplc on Twitter or
visit SmithNephewplc on Facebook.com.
Forward-looking Statements
This document may contain forward-looking statements that may
or may not prove accurate. For example, statements regarding
expected revenue growth and trading margins, market trends and our
product pipeline are forward-looking statements. Phrases such as
"aim", "plan", "intend", "anticipate", "well-placed", "believe",
"estimate", "expect", "target", "consider" and similar expressions
are generally intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that could cause actual
results to differ materially from what is expressed or implied by
the statements. For Smith & Nephew, these factors include:
economic and financial conditions in the markets we serve,
especially those affecting health care providers, payers and
customers; price levels for established and innovative medical
devices; developments in medical technology; regulatory approvals,
reimbursement decisions or other government actions; product
defects or recalls or other problems with quality management
systems or failure to comply with related regulations; litigation
relating to patent or other claims; legal compliance risks and
related investigative, remedial or enforcement actions; disruption
to our supply chain or operations or those of our suppliers;
competition for qualified personnel; strategic actions, including
acquisitions and dispositions, our success in performing due
diligence, valuing and integrating acquired businesses; disruption
that may result from transactions or other changes we make in our
business plans or organisation to adapt to market developments; and
numerous other matters that affect us or our markets, including
those of a political, economic, business, competitive or
reputational nature. Please refer to the documents that Smith &
Nephew has filed with the U.S. Securities and Exchange Commission
under the U.S. Securities Exchange Act of 1934, as amended,
including Smith & Nephew's most recent annual report on Form
20-F, for a discussion of certain of these factors. Any
forward-looking statement is based on information available to
Smith & Nephew as of the date of the statement. All written or
oral forward-looking statements attributable to Smith & Nephew
are qualified by this caution. Smith & Nephew does not
undertake any obligation to update or revise any forward-looking
statement to reflect any change in circumstances or in Smith &
Nephew's expectations.
™ Trademark of Smith & Nephew. Certain
marks registered US Patent and Trademark Office.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/smith--nephew-previews-navio-robotics-assisted-total-knee-application-at-aaos-ahead-of-full-market-release-in-q2-2017-300423654.html
SOURCE Smith & Nephew